Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 272-280

  Sobieszczyk, Magdalena E ^a   Hoover, Donald R ^b   Anastos, Kathryn ^c   Mulligan, Kathleen ^d   Tan, Tianren ^e   Shi, Qiuhu ^f   Gao, Wei ^g   Hyman, Charles ^h   Cohen, Mardge H ⁱ   Cole, Stephen R ^j   Plankey, Michael W ^k   Levine, Alexandra M ^l   Justman, Jessica ^m  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b RUTGERS UNIVERSITY   (United States)

^c LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Data Solutions LLC   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h KINGS COUNTY HOSPITAL CENTER   (United States)

ⁱ Jr Hospital of Cook County   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m Columbia University ^*  (United States)

more..

Author keywords

HIV; Metabolic syndrome; Prevalence; Women

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SMOKING; TIME SERIES ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ETHNIC GROUP; RISK FACTOR; SERODIAGNOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 47049111149     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817af461     Document Type: Article

References (64)

1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
2. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001;12:313-319.
3. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIVand its drug therapy. Ann Pharmacother. 2001;35:343-351.
4. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
5. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
6. Barbaro G, Barbarini G. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy. 2006;52: 161-165.
7. Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
9. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108:1541-1545.
10. Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
11. Grundy SM, Bazzarre T, Cleeman J, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation. 2000;101:E3-E11.
12. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med. 2006;38:34-41.
13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
14. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-1292.
15. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
16. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
17. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
19. Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care. 2004;27:2707-2715.
20. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
21. Zhu S, St-Onge MP, Heshka S, et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism. 2004;53:1503-1511.
22. Gazzaruso C, Sacchi P, Garzaniti A, et al. Prevalence of metabolic syndrome among HIV patients. Diabetes Care. 2002;25:1253-1254.
23. Palella F, Wang Z, Chu H, et al. Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the Multicenter AIDS Cohort Study. Paper presented at: Conference of Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.
24. Worm S, Sabin C, El-Sadr W, et al. The Metabolic Syndrome at baseline in the D:A:D study. Paper presented at: 8th International Congress on Drug Therapy in HIV Infection; Poster P124; November 12-16, 2006; Glasgow, Scotland.
25. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019.
26. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
27. Diggle P, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. Oxford, England: Oxford Science Publication; 1994.
28. Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007;45:426-431.
29. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension. 2005;45:1072-1077.
30. Tien PC, Stephen RC, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2003;34:461-466.
31. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab. 2001;12:413-419.
32. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003;36:909-916.
33. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989; 83:1168-1173.
34. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132-137.
35. Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002;31:363-365.
36. Mondy K, Tong S, Kessels L, et al. Metabolic Syndrome in HIV Within a Representative U.S. Population. Denver, CO: CROI; 2006.
37. Bergersen BM, Schumacher A, Sandvik L, et al. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis. 2006;38:682-689.
38. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and (corrected) hypoadiponectinemia. Diabetes Care. 2007;30:113-119.
39. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458-466.
40. Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726-734.
41. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294:1773-1781.
42. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
43. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153-3159.
44. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
45. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003;88:5186-5192.
46. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36:684-692.
47. van Leth F, Hall DB, Lange JM, et al. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med. 2006;7:347-350.
48. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
49. Bergersen BM, Tonstad S, Sandvik L, et al. Low prevalence of high-density lipoprotein cholesterol level <1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients. Int J STD AIDS. 2005;16: 365-369.
50. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviralnaive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585-591.
51. Mangili A, Jacobson D, Gerrior J, et al. Metabolic syndrome and markers of early atherosclerosis in a cohort of HIV-infected subjects from nutrition for healthy living. Paper presented at: CROI; February 22-25, 2005; Boston, MA.
52. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947.
53. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:332-340.
54. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005; 39:44-54.
55. Feldman JG, Goldwasser P, Holman S, et al. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210-214.
56. Henry K, Kitch D, Dube M, et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004; 18:2434-2437.
57. Sklar P, BW, Csako G, et al. C-reactive protein may be an important biomarker of cardiovascular risk and does not appear to be confounded by antiretroviral use or HIV viremia. Paper presented at: CROI; February 10-14, 2003; Boston, MA.
58. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
59. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-1839.
60. Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71(1):92-100.
61. Florez H, Silva E, Fernandez V, et al. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract. 2005;69:63-77.
62. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003;168:351-358.
63. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004;94:1249-1254.
64. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286: 327-334.